Assessing Inflammatory Markers in Benign Pathologies in Prostate, Lung, Colorectal and Ovarian Cancers

A study evaluated self-reported history of benign pathology and subsequent alterations in systemic inflammation in prostate, lung, colorectal, and ovarian cancer screening. The results appeared in Annals of Epidemiology.

Researchers assessed case-control studies from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. They evaluated associations between self-reported history of benign ovarian cysts, uterine fibroids, and endometriosis with inflammatory marker concentrations using logistic regression and meta-analysis.

The results showed that compared to women without a self-reported history of the pathology evaluated, benign ovarian cysts were associated with increased PAI-1 (odds ratio [OR] = 6.24, 95% confidence interval [CI] 2.53-15.39, P <0.001) and TGF-β1 (OR = 3.79; 95% CI, 1.62-8.86, P = 0.002) and decreased BCA-1 (OR = 0.38; 95% CI, 0.19-0.73, P = 0.004). The researchers noted that uterine fibroids were associated with decreased CXCL11 (OR = 0.37; 95% CI, 0.22-0.63, P <0.001), and VEGFR3 (OR = 0.40; 95% CI, 0.24-0.65, P <0.001).

Self-reported history of benign gynecologic pathologies were associated with alterations in inflammatory markers that have been previously linked to cancer risk. Understanding interactions between benign gynecologic pathologies and the systemic immune system may help inform disease risk later in life,” the researchers concluded.